title: Conjugated bile acid replacement therapy for short-bowel syndrome.
abstract: OBJECTIVE
  Although fat malabsorption in the short-bowel syndrome is caused in part by decreased bile acid secretion, bile acid replacement therapy is not used because of the belief that ingested bile acids would worsen diarrhea, outweighing the benefits of improved fat absorption. This study compared the effect of a natural conjugated bile acid mixture from ox bile with that of cholylsarcosine, a synthetic conjugated bile acid, on fat absorption and diarrhea in a patient with the short-bowel syndrome. Cholylsarcosine is resistant to bacterial metabolism and has no cathartic activity.
  
  
  METHODS
  Metabolic balance studies and a clinical trial were performed in an emaciated patient with the short-bowel syndrome and ileostomy in whom parenteral nutrition could not be used.
  
  
  RESULTS
  In balance studies, conjugated bile acid replacement therapy with either preparation caused fat absorption to increase by approximately 40 g/day. Calcium absorption also increased. Neither bile acid product caused a clinically significant increase in ileostomy water output. During a 4-month outpatient trial, while the patient ingested 2 g/meal natural bile acids, her weight increased from 80 to 98 lb, without side effects.
  
  
  CONCLUSIONS
  Conjugated bile acid replacement therapy should be part of the armamentarium for the treatment of selected patients with the short-bowel syndrome.
authors.affiliation: Department of Medicine, Baylor University Medical Center, Dallas, Texas, 75246, USA.
authors.forename: C
authors.initials: C
authors.lastname: Gruy-Kapral
authors.forename: K H
authors.initials: KH
authors.lastname: Little
authors.forename: J S
authors.initials: JS
authors.lastname: Fordtran
authors.forename: T L
authors.initials: TL
authors.lastname: Meziere
authors.forename: L R
authors.initials: LR
authors.lastname: Hagey
authors.forename: A F
authors.initials: AF
authors.lastname: Hofmann
mesh_terms: D000818:Animals; D001219:Aspartate Aminotransferases / Q000097:blood; D001647:Bile Acids and Salts / Q000009:adverse effects / Q000627:therapeutic use*; D001835:Body Weight / Q000187:drug effects; D002417:Cattle; D002793:Cholic Acids / Q000009:adverse effects / Q000627:therapeutic use; D003967:Diarrhea / Q000188:drug therapy; D004041:Dietary Fats / Q000378:metabolism; D002149:Energy Intake; D005243:Feces / Q000737:chemistry; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007081:Ileostomy; D007408:Intestinal Absorption; D008875:Middle Aged; D012521:Sarcosine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D012778:Short Bowel Syndrome / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology
chemical_list: D001647:Bile Acids and Salts; D002793:Cholic Acids; D004041:Dietary Fats; D001219:Aspartate Aminotransferases; C061997:cholylsarcosine; D012521:Sarcosine